Araştırma Makalesi
BibTex RIS Kaynak Göster

Relationship between neutrophil/lymphocyte, platelet/lymphocyte, CRP/Albumin ratio and survival in ovarian cancer

Yıl 2021, Cilt: 14 Sayı: 3, 666 - 674, 01.07.2021
https://doi.org/10.31362/patd.907695

Öz

Kaynakça

  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63(1):11–30.
  • 2. Morgan Jr RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.
  • 3. Holschneider, C.H. and J.S. Berek. Ovarian cancer: epidemiology, biology, and prognostic factors. In seminars in surgical oncology. 2000. Wiley Online Library
  • 4. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–740.
  • 5. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013;25:50–1.
  • 6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
  • 7. Nie W, Yu T, Sang Y, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochem Biophys Res Commun 2017;482:1400–1406.
  • 8. He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013; 30:439.
  • 9. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504–10.
  • 10. Liu X, Qu JK, Zhang J, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine 2017;96:e8101.
  • 11. Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-tolymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 2015;5:12493.
  • 12. Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:646–654.
  • 13. Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 2018;150:31–37.
  • 14. Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 2018;18:443.
  • 15. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111.
  • 16. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714.
  • 17. Zeng F, Wei H, Yeoh E, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25(8):1231–1239.
  • 18. Brower V. Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst. 2005;97(4):251–253.
  • 19. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012; 10:33.
  • 20. Williams KA, Intidhar LG , Terry KL, et al. Prognostic significance and predictors of the neutrophil-tolymphocyteratio in ovarian cancer. Gynecologic Oncol. 2014;132(3):542–550.
  • 21. Yuan-qiu Wang , Chu Jin , Hua-min Zheng, et al.A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clinica Chimica Acta 456 (2016) 163–169.
  • 22. Xinming Yin, Ling Wub , Hui Yang, HongBo Yang. Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer A systematic review and meta-analysis. Medicine (Baltimore) 2019 Nov;98(45):e17475.
  • 23. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated inepithelial ovarian cancer and predicts survival after treatment. CancerImmunol Immunother. 2009;58(1):15–23.
  • 24. Asher V, Lee J, Innamaa A, Bali A, et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Translat Oncol. 2011;13(7):499. Raungkaewmanee S, et al. Platelet to lymphocyte ratio as a prognostic fact.
  • 25. Zhang W-w, Liu K-j , Hu G-l , Wei-jiang Liang W-l, et al. Preoperative platelet/lymphocyte ratio is a superiorprognostic factor compared to other systemic inflammatory responsemarkers in ovarian cancer patients. Tumor Biol. 2015;36(11):8831–8837.
  • 26.Chuan Tian, Wei Song, Xia Tian , Yong Sun.Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis.Eur J Clin Invest. 2018 May;48(5).
  • 27. Yubo Liu, Shengfu Chen, Chengyu Zheng, et al.The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.BMC Cancer. 2017.
  • 28. Komura N, Mabuchi S, Shimura K, Kawano M, Matsumoto Y, Kimura T. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.Nutr Cancer. 2020 Aug 24:1-8.
  • 29. Peres LC, Mallen AR, Townsend MK, et al. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.Cancer Res. 2019 Oct 15;79(20):5442-5451.

Over kanserinde nötrofil/lenfosit, trombosit/lenfosit, CRP/Albümin oranları ile klinikopatolojik özellikler ve sağkalım arasındaki ilişki.

Yıl 2021, Cilt: 14 Sayı: 3, 666 - 674, 01.07.2021
https://doi.org/10.31362/patd.907695

Öz

Amaç: Over kanseri jinekolojik kanserler arasında en yüksek ölüm oranına sahip olan kanserdir.İnflamasyon temelli skorlar olan nötrofil lenfosit oranı (NLR), trombosit lenfosit oranı (PLR), CRP albümin oranı (CRP/Alb) çoğu kanserde prognoz üzerine etkisi gösterilmiştir. Biz de bu çalışmada NLR, PLR, CRP/Albümin oranlarının over kanserinin prognozu üzerine olan etkisini değerlendirmeyi amaçladık.

Gereç ve Yöntem: Çalışmamıza Eylül 2014 - Aralık 2020 tarihleri arasında Pamukkale Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı polikliniğine başvuran over karsinom tanılı 124 hasta çalışmaya alındı. Evre 1-4 arasında değişen toplam 124 hasta hasta çalışmaya dahil edildi. NLR, PLR, CRP/Albumin kesme noktaları ROC analizi ile yapıldı.


Bulgular: Hastalarımızın medyan yaşı 56 (sınırlar 24-84 ) idi. NLR oranı 63 hastada (%50), PLR oranı 56 hastada (%45), CRP/Alb oranı 61 hastada (%49) kesme değerine göre yüksek saptandı. PLR değeri ile progresyon sağkalım arasında istatistiksel olarak anlamlı ilişki yokken, genel sağkalımla istatistiksel olarak anlamlı ilişki bulunmaktaydı (p=0.01). PLR değeri yüksek olanlarda medyan genel sağkalım 23 ay iken PLR değeri düşük olanlarda 45 aydır olarak saptandı. CRP/Alb oranının ise hem progresyonsuz sağkalım hem de genel sağkalım ile istatistiksel olarak anlamlı ilişkisi mevcuttu (p=0.011; p=0.008). CRP/Alb değeri düşük olanlarda daha uzun progresyonsuz sağkalım ve genel sağkalım olduğu saptandı.


Sonuç: Diğer kanser tiplerinde olduğu gibi over kanserinde de inflamasyon belirteçlerinin kanser progresyonu üzerine dolayısıyla prognoza olan etkisi dikkat çekmektedir. PLR oranının genel sağkalımla, CRP/alb oranının ise hem genel sağkalım hemde progresyonsuz sağkalımla istatistiksel olarak anlamlı bir ilişkisi olduğunu gösterdik. Bu oranların gelecekte farklı tedavi gruplarını oluştururken hastaların seçiminde yardımcı olabileceği kanısındayız.

Kaynakça

  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63(1):11–30.
  • 2. Morgan Jr RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.
  • 3. Holschneider, C.H. and J.S. Berek. Ovarian cancer: epidemiology, biology, and prognostic factors. In seminars in surgical oncology. 2000. Wiley Online Library
  • 4. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–740.
  • 5. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013;25:50–1.
  • 6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
  • 7. Nie W, Yu T, Sang Y, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochem Biophys Res Commun 2017;482:1400–1406.
  • 8. He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013; 30:439.
  • 9. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504–10.
  • 10. Liu X, Qu JK, Zhang J, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine 2017;96:e8101.
  • 11. Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-tolymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 2015;5:12493.
  • 12. Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:646–654.
  • 13. Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 2018;150:31–37.
  • 14. Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 2018;18:443.
  • 15. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111.
  • 16. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714.
  • 17. Zeng F, Wei H, Yeoh E, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25(8):1231–1239.
  • 18. Brower V. Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst. 2005;97(4):251–253.
  • 19. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012; 10:33.
  • 20. Williams KA, Intidhar LG , Terry KL, et al. Prognostic significance and predictors of the neutrophil-tolymphocyteratio in ovarian cancer. Gynecologic Oncol. 2014;132(3):542–550.
  • 21. Yuan-qiu Wang , Chu Jin , Hua-min Zheng, et al.A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clinica Chimica Acta 456 (2016) 163–169.
  • 22. Xinming Yin, Ling Wub , Hui Yang, HongBo Yang. Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer A systematic review and meta-analysis. Medicine (Baltimore) 2019 Nov;98(45):e17475.
  • 23. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated inepithelial ovarian cancer and predicts survival after treatment. CancerImmunol Immunother. 2009;58(1):15–23.
  • 24. Asher V, Lee J, Innamaa A, Bali A, et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Translat Oncol. 2011;13(7):499. Raungkaewmanee S, et al. Platelet to lymphocyte ratio as a prognostic fact.
  • 25. Zhang W-w, Liu K-j , Hu G-l , Wei-jiang Liang W-l, et al. Preoperative platelet/lymphocyte ratio is a superiorprognostic factor compared to other systemic inflammatory responsemarkers in ovarian cancer patients. Tumor Biol. 2015;36(11):8831–8837.
  • 26.Chuan Tian, Wei Song, Xia Tian , Yong Sun.Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis.Eur J Clin Invest. 2018 May;48(5).
  • 27. Yubo Liu, Shengfu Chen, Chengyu Zheng, et al.The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.BMC Cancer. 2017.
  • 28. Komura N, Mabuchi S, Shimura K, Kawano M, Matsumoto Y, Kimura T. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.Nutr Cancer. 2020 Aug 24:1-8.
  • 29. Peres LC, Mallen AR, Townsend MK, et al. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.Cancer Res. 2019 Oct 15;79(20):5442-5451.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Onkoloji ve Karsinogenez
Bölüm Araştırma Makalesi
Yazarlar

Burcu Yapar Taşköylü 0000-0003-4755-2753

Esin Avcı 0000-0002-9173-0142

Atike Gökçen Demiray 0000-0003-4397-5468

Serkan Değirmencioğlu 0000-0002-1213-2778

Gamze Gokoz Dogu

Arzu Yaren

Ahmet Ergin 0000-0001-5236-7507

Derya Kılıç 0000-0001-8003-9586

Canan Karan Bu kişi benim 0000-0002-1293-2046

Burçin Çakan Demirel Bu kişi benim 0000-0003-0734-0692

Tolga Doğan Bu kişi benim 0000-0003-1281-942X

Melek Özdemir 0000-0003-1894-9743

Yayımlanma Tarihi 1 Temmuz 2021
Gönderilme Tarihi 2 Nisan 2021
Kabul Tarihi 3 Mayıs 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 14 Sayı: 3

Kaynak Göster

AMA Yapar Taşköylü B, Avcı E, Demiray AG, vd. Over kanserinde nötrofil/lenfosit, trombosit/lenfosit, CRP/Albümin oranları ile klinikopatolojik özellikler ve sağkalım arasındaki ilişki. Pam Tıp Derg. Temmuz 2021;14(3):666-674. doi:10.31362/patd.907695
Creative Commons Lisansı
Pamukkale Tıp Dergisi, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır